Glucose-conjugated glutenin nanoparticles for selective targeting and delivery of camptothecin into breast cancer cells

Rajeshkumar, Raja Rajeswari; Pavadai, Parasuraman; Panneerselvam, Theivendren; Deepak, Venkataraman; Pandian, Sureshbabu Ram Kumar; Kabilan, Shanmugampillai Jeyarajaguru; Sivakumar, Vellaichamy; Jeyaraman, Anbu; Kumar, Amit; Sundar, Krishnan; Kunjiappan, Selvaraj

doi:10.1007/s00210-023-02480-y

Cited by 6 publications

(4 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Glu-CPT-glutenin NPs are spherical in shape, 200 nm in size, and have concentration-dependent cytotoxicity against MCF-7 cells (IC 50 = 18.23 μg mL –1 ). 84 The cellular uptake study shows enhanced endocytosis and effective delivery of CPT in MCF-7 cells. The NPs also target mitochondria, enhancing reactive oxygen species (ROS) levels and damaging mitochondrial membrane integrity.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 95%

“…FT-IR and 13C-NMR spectra confirmed the conjugation. The Glu-CPT-glutenin NPs are spherical in shape, 200 nm in size, and have concentration-dependent cytotoxicity against MCF-7 cells (IC 50 = 18.23 μg mL –1 ) . The cellular uptake study shows enhanced endocytosis and effective delivery of CPT in MCF-7 cells.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…The cellular uptake study shows enhanced endocytosis and effective delivery of CPT in MCF-7 cells. The NPs also target mitochondria, enhancing reactive oxygen species (ROS) levels and damaging mitochondrial membrane integrity . Thus, from the outcomes, it summarized that the wheat glutenin can be proposed as a delivery carrier in the enhancement of anticancer drugs.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

See 2 more Smart Citations

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 95%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Glutenin was extracted from wheat grains according to our previously published work [40]. FTIR and 13 C-NMR spectroscopy were used to con rm the extracted glutenin before it was proceeded for nanoparticle formulation.…”

Section: Glutenin Extractionmentioning

confidence: 99%

Enhanced delivery of retinoic acid to breast cancer cells by folate receptor- targeted folic acid-conjugated glutenin nanoparticles for promising treatment of breast cancer

Rajeshkumar,

Pavadai,

Panneerselvam

et al. 2023

Preprint

View full text Add to dashboard Cite

Targeted delivery via surface receptors can significantly improve the therapeutic efficacy and reduce the adverse drug reactions. The protein nanocarrier system offers many advantages, such as encapsulation in various drugs and molecules and prolonged circulation. Here, the folate receptor-targeted folic acid-conjugated retinoic acid-loaded glutenin nanoparticles (FA-RA-Glu NPs) were successfully synthesised for enhanced delivery of retinoic acid to breast cancer cells (MCF-7). After a complete physico-chemical characterisation of FA-RA-Glu NPs, stability, drug release, release kinetics, cytotoxicity, apoptosis, cell death, and nucleic acid fragmentation were analysed. The results showed that FA-RA-Glu NPs were ⁓185 nm in size, predominantly spherical in shape, crystalline in nature and had a zeta potential of − 3 mV. The RA encapsulation efficiency and loading capacity of Glu NPs were 83.537% ± 3.32% and 9.917 ± 1.68%, respectively. The effects of FA-RA-Glu NPs against MCF-7 cells significantly reduced the number of viable cells and the induction of apoptosis. The cellular uptake study showed that the FA-RA-Glu NPs had facilitated endocytosis and delivered RA into MCF-7 cells. After treatment with FA-RA-Glu NPs, contracted nuclei and deformed membrane bodies were observed as typical apoptotic morphological changes. The released RA also targeted the mitochondria of MCF-7 cells, which significantly increased the levels of reactive oxygen species and contributed to the damage of mitochondrial membrane integrity. These results suggest that FA-RA-Glu NPs with facilitated endocytosis and targeted delivery of RA into MCF-7 cells may have significant therapeutic potential for the treatment of breast cancer.

show abstract

Enhanced Delivery of Retinoic Acid to Breast Cancer Cells by Folate Receptor-Targeted Folic Acid-Conjugated Glutenin Nanoparticles for Promising Treatment of Breast Cancer

Rajeshkumar,

Pavadai,

Panneerselvam

et al. 2023

J Polym Environ

Self Cite

View full text Add to dashboard Cite

Targeted delivery via surface receptors can signi cantly improve the therapeutic e cacy and reduce the adverse drug reactions. The protein nanocarrier system offers many advantages, such as encapsulation in various drugs and molecules and prolonged circulation. Here, the folate receptor-targeted folic acidconjugated retinoic acid-loaded glutenin nanoparticles (FA-RA-Glu NPs) were successfully synthesised for enhanced delivery of retinoic acid to breast cancer cells (MCF-7). After a complete physico-chemical characterisation of FA-RA-Glu NPs, stability, drug release, release kinetics, cytotoxicity, apoptosis, cell death, and nucleic acid fragmentation were analysed. The results showed that FA-RA-Glu NPs were 185 nm in size, predominantly spherical in shape, crystalline in nature and had a zeta potential of − 3 mV. The RA encapsulation e ciency and loading capacity of Glu NPs were 83.537% ± 3.32% and 9.917 ± 1.68%, respectively. The effects of FA-RA-Glu NPs against MCF-7 cells signi cantly reduced the number of viable cells and the induction of apoptosis. The cellular uptake study showed that the FA-RA-Glu NPs had facilitated endocytosis and delivered RA into MCF-7 cells. After treatment with FA-RA-Glu NPs, contracted nuclei and deformed membrane bodies were observed as typical apoptotic morphological changes. The released RA also targeted the mitochondria of MCF-7 cells, which signi cantly increased the levels of reactive oxygen species and contributed to the damage of mitochondrial membrane integrity. These results suggest that FA-RA-Glu NPs with facilitated endocytosis and targeted delivery of RA into MCF-7 cells may have signi cant therapeutic potential for the treatment of breast cancer.

show abstract

Glucose-conjugated glutenin nanoparticles for selective targeting and delivery of camptothecin into breast cancer cells

Cited by 6 publications

References 73 publications

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Enhanced delivery of retinoic acid to breast cancer cells by folate receptor- targeted folic acid-conjugated glutenin nanoparticles for promising treatment of breast cancer

Enhanced Delivery of Retinoic Acid to Breast Cancer Cells by Folate Receptor-Targeted Folic Acid-Conjugated Glutenin Nanoparticles for Promising Treatment of Breast Cancer

Contact Info

Product

Resources

About